FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205235563> ?p ?o ?g. }

• W4205235563 endingPage "419" @default.
• W4205235563 startingPage "419" @default.
• W4205235563 abstract "419 Background: JCOG1113 (UMIN000001685) is a randomized phase III trial in patients (pts) with advanced biliary tract cancers (BTCs) that shows the non-inferiority of gemcitabine plus S-1 (GS) to gemcitabine plus cisplatin (GC) regarding overall survival (OS). Previous reports suggest that a history of major hepatectomy (MH) may affect dose intensity and adverse event (AE) frequency and reduce treatment efficacy in chemotherapy due to impairment of liver function and drug metabolism. We thus investigated whether a history of MH affects the frequency of AEs and treatment efficacy in recurrent BTC pts in JCOG1113. Methods: Among the 354 pts enrolled in JCOG1113, 76 recurrent pts with recurrence after surgery were included in this analysis. We compared the frequency of AEs, progression-free survival (PFS), and OS of GC vs. GS in pts treated with MH vs. non-major hepatectomy (NMH). Results: Of the 76 pts, 17 on GC and 13 on GS were included in the MH group, while 20 on GC and 26 on GS were included in the NMH group. The primary sites were only intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma in the MH group, and there were no differences between the groups regarding sex, performance status, biliary drainage, or site of recurrence. The hazard ratio (HR) of GS to GC for PFS was 0.74 (95% CI 0.35–1.56) in the MH group and 0.97 (95% CI 0.52–1.82) in the NMH group. The hazard ratio (HR) of GS to GC for OS was 0.99 (95% CI 0.418–2.36) in the MH group and 1.17 (95% CI 0.59–2.33) in the NMH group. The median PFS and OS for GS in the MH group were 12.2 months and 21.5 months. These were longer than the 6.8 months and 15.1 months in the original results for GS in JCOG1113. Regarding AEs, Grade 3-4 AEs, specifically neutrophil count decreased (73.1%/92.3%), platelet count decreased (3.9%/15.4%), and rash (7.7%/15.4%), were more common in MH pts than NMH pts on GS. On GC, AEs in the MH and NMH pts did not show any consistent trends. The relative dose intensities (RDIs) of gemcitabine (70.7%/62.5%) and S-1 (70.4%/54.5%) were lower in MH pts than NMH pts on GS. The RDIs of gemcitabine (67.4%/63.0%) and cisplatin (73.6%/65.0%) were slightly lower in MH pts than NMH pts on GC. Conclusions: For pts with a history of MH, some AEs increased, and the RDIs were lower, especially that of S-1 for GS. On the other hand, the HR for PFS suggests that GS may be more effective than GC in MH pts." @default.
• W4205235563 created "2022-01-25" @default.
• W4205235563 creator A5001038023 @default.
• W4205235563 creator A5005262911 @default.
• W4205235563 creator A5015481734 @default.
• W4205235563 creator A5021509769 @default.
• W4205235563 creator A5022537134 @default.
• W4205235563 creator A5039783762 @default.
• W4205235563 creator A5043799958 @default.
• W4205235563 creator A5045601646 @default.
• W4205235563 creator A5050530209 @default.
• W4205235563 creator A5056197140 @default.
• W4205235563 creator A5057311746 @default.
• W4205235563 creator A5058232958 @default.
• W4205235563 creator A5058782853 @default.
• W4205235563 creator A5064905706 @default.
• W4205235563 creator A5065581439 @default.
• W4205235563 creator A5069127455 @default.
• W4205235563 creator A5074627346 @default.
• W4205235563 creator A5076696174 @default.
• W4205235563 creator A5076981597 @default.
• W4205235563 creator A5078389128 @default.
• W4205235563 date "2022-02-01" @default.
• W4205235563 modified "2023-10-16" @default.
• W4205235563 title "The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113." @default.
• W4205235563 doi "https://doi.org/10.1200/jco.2022.40.4_suppl.419" @default.
• W4205235563 hasPublicationYear "2022" @default.
• W4205235563 type Work @default.
• W4205235563 citedByCount "0" @default.
• W4205235563 crossrefType "journal-article" @default.
• W4205235563 hasAuthorship W4205235563A5001038023 @default.
• W4205235563 hasAuthorship W4205235563A5005262911 @default.
• W4205235563 hasAuthorship W4205235563A5015481734 @default.
• W4205235563 hasAuthorship W4205235563A5021509769 @default.
• W4205235563 hasAuthorship W4205235563A5022537134 @default.
• W4205235563 hasAuthorship W4205235563A5039783762 @default.
• W4205235563 hasAuthorship W4205235563A5043799958 @default.
• W4205235563 hasAuthorship W4205235563A5045601646 @default.
• W4205235563 hasAuthorship W4205235563A5050530209 @default.
• W4205235563 hasAuthorship W4205235563A5056197140 @default.
• W4205235563 hasAuthorship W4205235563A5057311746 @default.
• W4205235563 hasAuthorship W4205235563A5058232958 @default.
• W4205235563 hasAuthorship W4205235563A5058782853 @default.
• W4205235563 hasAuthorship W4205235563A5064905706 @default.
• W4205235563 hasAuthorship W4205235563A5065581439 @default.
• W4205235563 hasAuthorship W4205235563A5069127455 @default.
• W4205235563 hasAuthorship W4205235563A5074627346 @default.
• W4205235563 hasAuthorship W4205235563A5076696174 @default.
• W4205235563 hasAuthorship W4205235563A5076981597 @default.
• W4205235563 hasAuthorship W4205235563A5078389128 @default.
• W4205235563 hasConcept C126322002 @default.
• W4205235563 hasConcept C141071460 @default.
• W4205235563 hasConcept C143998085 @default.
• W4205235563 hasConcept C159110652 @default.
• W4205235563 hasConcept C197934379 @default.
• W4205235563 hasConcept C207103383 @default.
• W4205235563 hasConcept C2775982439 @default.
• W4205235563 hasConcept C2776694085 @default.
• W4205235563 hasConcept C2776909242 @default.
• W4205235563 hasConcept C2780258809 @default.
• W4205235563 hasConcept C3017919176 @default.
• W4205235563 hasConcept C44249647 @default.
• W4205235563 hasConcept C71924100 @default.
• W4205235563 hasConcept C90924648 @default.
• W4205235563 hasConceptScore W4205235563C126322002 @default.
• W4205235563 hasConceptScore W4205235563C141071460 @default.
• W4205235563 hasConceptScore W4205235563C143998085 @default.
• W4205235563 hasConceptScore W4205235563C159110652 @default.
• W4205235563 hasConceptScore W4205235563C197934379 @default.
• W4205235563 hasConceptScore W4205235563C207103383 @default.
• W4205235563 hasConceptScore W4205235563C2775982439 @default.
• W4205235563 hasConceptScore W4205235563C2776694085 @default.
• W4205235563 hasConceptScore W4205235563C2776909242 @default.
• W4205235563 hasConceptScore W4205235563C2780258809 @default.
• W4205235563 hasConceptScore W4205235563C3017919176 @default.
• W4205235563 hasConceptScore W4205235563C44249647 @default.
• W4205235563 hasConceptScore W4205235563C71924100 @default.
• W4205235563 hasConceptScore W4205235563C90924648 @default.
• W4205235563 hasIssue "4_suppl" @default.
• W4205235563 hasLocation W42052355631 @default.
• W4205235563 hasOpenAccess W4205235563 @default.
• W4205235563 hasPrimaryLocation W42052355631 @default.
• W4205235563 hasRelatedWork W1849033 @default.
• W4205235563 hasRelatedWork W1911331 @default.
• W4205235563 hasRelatedWork W19973245 @default.
• W4205235563 hasRelatedWork W2293350 @default.
• W4205235563 hasRelatedWork W2544042 @default.
• W4205235563 hasRelatedWork W2789219 @default.
• W4205235563 hasRelatedWork W4018899 @default.
• W4205235563 hasRelatedWork W4112738 @default.
• W4205235563 hasRelatedWork W415001 @default.
• W4205235563 hasRelatedWork W4908868 @default.
• W4205235563 hasVolume "40" @default.
• W4205235563 isParatext "false" @default.
• W4205235563 isRetracted "false" @default.
• W4205235563 workType "article" @default.